COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 26, 2017
app pub date -
Jul 21, 2016
filing date -
Jul 22, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods for treating cancer include administering a therapeutically effective amount of an immunomodulatory agent such as interferon gamma 1b in combination with a therapeutically effective amount of a PD-1 checkpoint inhibitor such as nivolumab or pembrolizumab or a therapeutically effective amount of a PD-L1 checkpoint inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully